Summary: To clarify the cause of the canine individual variability in plasma concentration after oral administration of GTS-21, we evaluated in vitro the metabolism to 4-OH-GTS-21 in liver microsomes of the same individuals from in vivo pharmacokinetic study. First, we applied to the Michaelis-Menten kinetic parameters to a dispersion model, and compared hepatic availability (F H ) and hepatic clearance (CL H ) values from in vitro with bioavailability (F ), hepatic plasma ‰ow (Q PH ), and plasma clearance (CL P ) values from in vivo. The ratios of CL H to Q PH were ranged 0.74 to 0.94, suggesting that GTS-21 is a hepatic plasma ‰ow-limiting drug. A signiˆcant correlation of F H and F in the four dogs (r＝0.995, p＝ 0.005) indicates that the variability is predominantly caused by GTS-21 O 4-demethylase activity. Second, we speciˆed the cytochrome P450 (CYP) enzymes that are involved with the metabolism by chemical inhibition. a-Naphtho‰avone, furafylline, quinidine, quinine, and troleandomycin signiˆcantly inhibited GTS-21 O 4-demethylase activity. Thus CYP1A, CYP2D15, and CYP3A12 were involved with O 4-demethylation. The variability in control activity decreased on addition of a-naphtho‰avone and furafylline. Third, we quantiˆed the contents of CYP1A and CYP3A12 by enzyme-linked immunosorbent assay. The content of CYP1A was consistent with GTS-21 O 4-demethylase activity. We concluded that canine liver CYP1A causes the individual variability in GTS-21 plasma concentration after oral administration.
Introduction
Canine models have the advantages of providing consecutive data on the plasma concentration of individuals, allowing the use of formulations, 1, 2) ease of handling, and an abundance of background data. Dogs thus are widely used for pharmacokinetic and toxicokinetic studies. However, they occasionally show individual variability in the plasma concentration after oral administration.
3) The variability often complicates the analysis of the results. In some cases, it may be necessary to repeat or add a study, delaying research and development. To make matters worse, one may have to abandon the development of valuable drug candidates in the pre-clinical stage due to the variability. Thus, we consider it important to clarify the cause of the variability. Clariˆcation would provide precious information for the selection of appropriate animals to evaluate results more accurately.
The model compound, GTS-21, (Fig. 1 , also referred to as DMXB or DMXBA), (E )-3-(2,4-dimethoxybenzylidene)-3,4,5,6-tetra-hydro-2,3?-bipyridine dihydrochloride, has been developed to treat Alzheimer's disease 4) and schizophrenia. 5) In a previous work, 6) we evaluated the absorption ratio (FA), intestinal availability (FG), and hepatic availability (FH) in three dogs. GTS-21 was completely absorbed but lost byˆrst-pass eŠects of passage through the gut wall and liver. Theˆrst-pass eŠect of liver (Mean ±S.D., 0.100±0.063) is larger than that of gut wall (0.455±0.006), and dominates the individual variability in plasma concentration. GTS-21 is mainly metabolized to 4-OH-GTS-21 ( Fig. 1) and conjugated glucuronide. 7) We therefore focussed on in vitro metabolism of GTS-21 to 4-OH-GTS-21 in the liver microsomes of individuals, for which we had obtained in vivo pharmacokinetic data.
The purpose of our study is the elucidation of GTS-21 O 4-demethylase activity as the main cause of variable pharmacokinetics of GTS-21 in dogs. To estimate the contribution of the metabolism to total clearance, we subjected Michaelis-Menten kinetic parameters of four dogs to a scaling procedure. 8) A comparison of the in vivo pharmacokinetic parameters with the in vitro kinetic parameters revealed that the individual variability in plasma concentration was predominantly caused by GTS-21 O 4-demethylase activity. Next, we speciˆed the cytochrome P450 (CYP) enzymes that are involved with the metabolism by chemical inhibition, and quantiˆed the contents of key enzymes by enzyme-linked immunosorbent assays (ELISA).
Methods

Chemicals
GTS-21 and 4-OH-GTS-21 were synthesized at Chemical Lab, Taiho Pharmaceutical Co., Ltd. (Hanno, Japan). a-Naphtho‰avone, sulfaphenazole, troleandomycin, quinidine, and quinine were purchased from Sigma-Aldrich Japan K. K. (Tokyo, Japan). Coumarin and p-nitrophenol were purchased from Nacalai Tesque, Inc. (Kyoto, Japan). Furafylline, anti-rabbit IgG HRP-linked antibody, anti-dog CYP1A serum, and anti-dog CYP3A12 serum for ELISA were purchased from Daiichi Pure Chemicals Co., Ltd. (Tokyo, Japan). The products of anti-dog serum contain microsome standard and antiserum. All other reagents were of the highest purity commercially available. Water was puried with Milli-Q (Millipore, Tokyo, Japan).
In Vivo Pharmacokinetics of GTS-21
The Taiho Animal Investigation Committee approved the study protocol. Four male beagle dogs (30 months old; Dog-1, 15.0 kg; Dog-2, 11.4 kg; Dog-3, 11.6 kg; Dog-4, 14.4 kg) were purchased from Covance Research Product Inc. (Kalamazoo, MI). They were fasted with free access to water for 16 h before and fasted 4 h after administration. GTS-21 was dissolved in distilled water (2 mg W ml) into an amber glass container due to the photosensitivity of GTS-21. The dogs were administered GTS-21 (1 mg W kg) intravenously. Blood (2 ml) was collected with a heparinized syringe from the jugular vein at 5, 10, 15, 30, 45, 60, 120, and 240 min after administration. Also in the fasted condition, dogs were administered GTS-21 (1 mg W kg) orally, then tap water (30 ml) was ‰ushed into the stomach. Blood (2 ml) was collected with a heparinized syringe from the jugular vein at 15, 30, 45, 60, 90, 120, and 150 min after administration. The washout period was more than one week. Plasma was separated by centrifugation at 1,200 g, 49 C, for 15 min and stored at "809 C until analysis. Plasma sample preparations (0.25 ml) and the HPLC conditions were previously described. 9) Maximum plasma concentration (Cmax, ngW ml), time to reach Cmax (tmax, min), area under the plasma concentration versus time curve zero to inˆnity (AUC0"/, ng・h W ml), elimination half-life (t1W 2, min), plasma clearance (CLP, ml W min W kg), and bioavailability (F ) were calculated with a non-compartment model using Win-Nonlin Ver. 1.1 (Pharsight, Apex, NC). The elimination phase was analyzed by weighing 1 W y automatically.
Preparation of Dog Liver Microsomes
Three months after the pharmacokinetic study, the four dogs were weighed (Dog-1, 15.1 kg; Dog-2, 11.6 kg; Dog-3, 11.6 kg; Dog-4, 14.3 kg) and euthanized under thiopental anesthesia (0.5 ml W kg, i.v.). The livers were removed. Subsequent procedures were conducted in an ice-packed container. Livers were homogenized in the mixture buŠer of 0.1 M potassium phosphate buŠer (pH 7.4), 0.125 M KCl, and 1 mM EDTA.
10) The homogenates wereˆrst centrifuged at 9,000 g for 20 min, and then the supernatants were centrifuged at 105,000 g for 60 min. The microsomal pellets were re-suspended in the mixture buŠer, and then centrifuged at 105,000 g for 60 min. The pellets were resuspended in the mixture buŠer. The microsomal suspensions of the four dogs were individually stored at "809 C. Protein concentration was determined at 595 nm using a Bio-Rad Protein Assay Kit (Tokyo, Japan) with bovine serum albumin as a standard. Microsome contents were calculated using Eq. (1).
Microsome contents＝
Microsome concentration×Volume Liver weight for microsome preparation × Liver weight Body weight .
(1)
4. GTS-21 O 4-Demethylase Activity in Dog Liver Microsomes The procedures were conducted under yellow light. GTS-21 was dissolved in water. The microsomal mixture (200 ml, n＝3) contained 40 mg protein, 0.1 M potassium phosphate buŠer (pH 7.4), 25 mM KCl, 5 mM MgCl2, 0.2 mM EDTA, 1 mM NADPH, and GTS-21 (1, 2, 5, 10, 20, 50, 100, and 200 mM). The mixtures without NADPH solution were pre-incubated for 1 min at 379 C, then added NADPH solution. The mixtures were incubated for 1 min. The reaction was stopped by addition of ice-cold 10z HClO4 (200 ml), and the samples vortexed for 5 s. The samples were centrifuged at 1,200 g for 5 min at 49 C. The supernatants (40 ml) were injected into an HPLC system. HPLC conditions were as follows: analytical column, Hydrosphere C18 (3 mm, 100×4.6 mm i.d, YMC, Kyoto, Japan); column temperature, 409 C; mobile phase, 0.06z tri‰uoroacetic acid W acetonitrile (19 W 81); detection, UV-405 nm; ‰ow rate, 1.0 ml W min.
Protein Binding of GTS-21 in Microsomal Incubation and Plasma
The microsomal mixtures without NADPH (1-200 mM GTS-21, n＝4) were centrifuged at 105,000 g, and 379 C for 65 min. The mixtures were de-proteinized, and the supernatants were injected into the HPLC system. Plasma spiked with 6.6 mM GTS-21 (200 ml, n＝4) was incubated at 379 C for 15 min, then centrifuged at 194,000 g, and 379 C for 22 h. Supernatants were de-proteinized, and the supernatants were injected into the HPLC system. The mean unbound fractions of microsomal incubation were calculated by regression analysis.
Application
of Michaelis-Menten Kinetic Parameters Using a Scaling Procedure Hepatic plasma ‰ow (Q PH , mlW min W kg) was (1-Hematocrit) multiplied by hepatic blood ‰ow.
11) Allometric Eq. (2) is shown below. The hematocrit value was determined by the cumulative pulse height detection method using an automatic hematology analyzer NE-600 (SYSMEX, Tokyo, Japan).
Body weight ×1000.
Michaelis-Menten kinetic parameters of a twoenzymatic model, Eq. (3), maximum velocity (Vmax1 and Vmax2, nmolW min W mg protein) and Michaelis constant (Km1 and Km2, mM), were calculated by the damping Gauss-Newton method in MULTI.
12) Eadie-Hofstee plots were drawn using the unbound concentration of GTS-21, [S]un, and the metabolic velocity of 4-OH-GTS-21, v.
Hepatic intrinsic clearance (CLH,int, mlW min W kg) was calculated from Eq. (4).
Km2 » ×Microsome Contents. (4) The predicted values, F H and hepatic clearance (CL H , ml W min W kg), were calculated by applying QPH, plasma unbound fraction ( fu), CLH,int, and a dispersion number (DN) of 0.17 to the dispersion model, 8) Eqs. (5) and (6) .
In these Eqs., where a＝(1+4RN・DN) 1 W 2 , where RN (e‹ciency number)＝f u ・CL H,int W Q PH .
Chemical Inhibition Study of GTS-21 O 4-
Demethylase Activity a-Naphtho‰avone, furafylline, coumarin, sulfaphenazole, quinidine, quinine, p-nitrophenol, and troleandomycin were dissolved in 2z dimethylsulfoxide. Microsomal mixtures (200 ml containing 0.5z dimethylsulfoxide, n＝2) contained 50 mg protein, 0.1 M potassium phosphate buŠer (pH 7.4), 25 mM KCl, 50 mM EDTA, 5 mM MgCl 2 , 2 mM NADPH, 131 mM GTS-21, and 10 mM chemical inhibitor. When a-naphtho‰avone or a mechanism-based inhibitor (furafylline or troleandomycin) was included, the mixtures without GTS-21 were pre-incubated for 15 min at 379 C, then GTS-21 was added and incubated for 1 min. When the other inhibitor was included or not (control), the mixtures without NADPH were pre-incubated for 1 min at 379 C, then NADPH was added and incubated for 1 min. Subsequent procedures were the same as the determination of GTS-21 O 4-demethylase activity.
Enzyme Linked Immunosorbent Assay for Canine
CYP1A and 3A12 The contents of cytochrome P450 were determined by the usual method.
13) The contents of CYP1A and CYP3A12 were quantiˆed according to Eguchi et al.
14)
The microsomal suspension was diluted with phosphate buŠered saline to 6.6-10 mg W ml for CYP1A quantiˆca-tion and 2.5-4.0 mg W ml for CYP3A12 quantiˆcation, respectively. To prepare TMB solution, 15 mg 3,3?,5,5?-tetramethylbenzidine (TMB) was dissolved in 15 ml dimethylsulfoxide, and then added to 85 ml buŠer (0.1 M citric acid-0.2 M Na 2 HPO 4 , pH 4.5). Just before use, H2O2 was added to the TMB solution at 0.012z.
Statistics
Statistics were calculated with EXSAS Ver. 5.00 (Arm 
Results
Pharmacokinetics of GTS-21 in Four Dogs
GTS-21 (1 mg W kg) was orally and intravenously administered to four fasted dogs. Plasma concentrations in all dogs peaked within 30 min and GTS-21 was eliminated rapidly with a t1W 2 of 29 to 47 min. The pharmacokinetic parameters, tmax, Cmax, AUC0"/, and t1W 2, of GTS-21 are shown in Table 1 . The elimination rate from plasma in individuals varied little, but a 7-fold diŠerence in the AUC 0"/ between maximum and minimum values was observed. In contrast, less than a 2-fold diŠerence was observed after intravenous administration. The t1W 2 values in all dogs were consistent with those after oral administration. The F values of Dogs-1 to 4 were 0.143, 0.125, 0.033, and 0.020, respectively.
GTS-21 O 4-Demethylase Activity in Dog Liver
Microsomes The metabolic velocities of GTS-21 O 4-demethylation were larger in Dogs-1, 3, and 4 than Dog-2 and within the range 1 to 200 mM. As shown in Fig. 2 , Eadie-Hofstee plots of all dogs showed biphasic kinetics. The Michaelis-Menten kinetic parameters, Vmax and Km, were analyzed with a two-enzymatic model. These parameters are listed in Table 2 . The K m1 value of Dog-1 was larger than those of Dogs-2, 3 and 4. The ratios of Vmax1 to Km1 of Dogs-3 and 4 were 2-fold more than the ratios of Dogs-1 and 2.
Hepatic Clearance and Hepatic Availability Using a
Scaling Procedure The CLH,int values were calculated by applying Michaelis-Menten kinetic parameters to Eq. (4). The diŠerence of CLH,int was 3-fold between maximum and minimum values. The hematocrit values of Dogs-1 to 4 were 0.453, 0.538, 0.482, and 0.428, respectively. The QPH values were calculated by applying the hematocrit values and body weight of the in vivo pharmacokinetic study to Eq. (2). The unbound fraction in microsomal incubation increased with the concentration of GTS-21. The regression equation was as follows: y＝x 0.0474 ×exp ("0.344), where x is substrate concentration (r＝0.948). The mean unbound fraction in plasma, fu, was 0.21. The predicted values, FH and CLH, were calculated using a dispersion model of Eqs. (5) and (6) . These parameters and F and CLP from the in vivo study are listed in Table 3 . The ratios of predicted CLH to QPH of Dogs-1 to 4 were 0.74, 0.77, 0.94, and 0.93, respectively. In addition, the ratios of CLH to CLP of Dogs-1 to 4 were 0.81, 0.50, 0.66, and 1.1, respectively. The individual variability of predicted FH corresponded well with that of F, a signiˆcant correlation (r＝0.995, p＝0.005) being obtained. One assay group was a-naphtho‰avone, coumarin, sulfaphenazole, quinidine, p-nitrophenol, and troleandomycin. The other assay group was furafylline and quinine. Signiˆcant diŠerences were analyzed by Dunnet's multiple comparison: *, pº0.05; **, pº0.01; ***, pº0.001. 
EŠect of CYP Chemical Inhibitors on GTS-21 O 4-Demethylation
Contents of Canine CYP1A and CYP3A12
CYP1A, CYP3A12, and cytochrome P450 contents and mean, S.D., and zR.S.D. are summarized in Table 4 . The cytochrome P450 contents of Dogs-1 to 4 indicate little individual variability. The CYP1A contents of Dogs-1 and 2 were half those of Dogs-3 and 4. The zR.S.D. for CYP1A was notably greater (49.0z) than that of CYP3A12 (6.8z) and cytochrome P450 (9.1z).
Discussion
The focus of our study was to resolve the cause of canine individual variability in the plasma concentration of GTS-21 after oral administration. To this end, we applied to the in vitro Michaelis-Menten kinetic parameters in the metabolism to O 4-demethylation, and compared the predicted FH and CLH values from in vitro with the actual F, CL P , and Q PH values from in vivo. In addition, we speciˆed by chemical inhibitors and quantiˆed the enzymes that are involved with the metabolism.
Four dogs were administered GTS-21 orally, the AUC 0"/ values of Dogs-1 and 2 being 4 to 7-fold larger than those of Dogs-3 and 4. Similarly, the Cmax values of Dogs-1 and 2 were larger than those of Dogs-3 and 4, but the t1W 2 values did not diŠer. In a previous work, 6) the bioavailability of GTS-21 in three dogs was 0.072, 0.021, and 0.037, respectively. The absorption ratio was close to 1, and the intestinal availability ranged from 0.449 to 0.461. The hepatic availability was estimated at 0.170, 0.047, and 0.083. We considered that theˆrst-pass eŠect through the liver is the key step. We therefore shifted our attention to the metabolism, namely, GTS-21 O 4-demethylase activity in the liver microsomes.
To estimate the initial metabolic velocity accurately, we investigated the linearity of the reaction time for GTS-21 O 4-demethylase activity. The formation of 4-OH-GTS-21 was fast enough to necessitate a 1-min incubation. Also, a 1-min preincubation at 379 C was adequate for thermal equilibration. Relatively low CLH,int values, 135 and 130 ml W min W kg, were obtained from liver microsomes of Dogs-1 and 2 that showed high Cmax and AUC0"/ values in vivo. High CLH,int values, 322 and 337 ml W min W kg, were obtained from those of Dogs-3 and 4 that showed low Cmax and AUC0"/ values.
Prior to scaling, we paid attention to the following three points; 1) choice of an appropriate scaling model, 2) protein binding on microsomal incubation, and 3) application of hepatic plasma ‰ow rate. We chose a dispersion model because it is most suitable for high clearance drugs. 15) Iwatsubo et al. 15) reported that the FH of high clearance drugs would be underestimated by a wellstirred model and overestimated by a parallel-tube model.
Next, we took protein binding into account at every substrate concentration in the microsomal incubation, and recalculated free GTS-21. The free GTS-21 increased from 0.71 to 0.91 with the concentration of 1 to 200 mM. Finally, to compare actual CLP with predicted CLH we applied QPH instead of hepatic blood ‰ow, and obtained predicted CLH and FH.
The ratio of CL H to Q PH ranged 0.74 to 0.94, suggesting that GTS-21 is a hepatic plasma ‰ow-limiting drug. With GTS-21 it is easy to obtain aˆrst-pass eŠect, and the elimination of GTS-21 is apt to be aŠected by the hepatic plasma ‰ow rate. The t1W 2 values after oral administration in individuals were not diŠerent in spite of the large individual variability of Cmax or AUC0"/. Thiŝ nding supports that the metabolism of GTS-21 depends on hepatic plasma ‰ow. The ratio of CLH to CLP varied from 0.50 to 1.1, suggesting that GTS-21 eliminated primarily via metabolism to O 4-demethylation.
Although the AUC0"/ after intravenous administration in Dog-4 was highest in four dogs, the variability was small. On the contrary, AUC0"/ after oral administration in Dog-4 was lowest. The AUC0"/ after oral administration is decreased by theˆrst-pass eŠect through the liver. The FH of a high clearance drug is more in‰uenced by fu ・CL H,int than QPH. There was no individual variability in fu in all dogs. Therefore the variability of the CLH,int re‰ects that of FH.
A discrepancy between CL H and CL P may be attributed to the excretory clearance of GTS-21 via bile and the non-actual measurement of QPH values.
A signiˆcant correlation of FH and F in the four dogs indicates that the individual variability in the plasma concentration of GTS-21 is predominantly caused by GTS-21 O 4-demethylase activity in the liver microsomes. We did not investigate the intestinal metabolism in small intestine because FG values were not variable in previous work.
6) The products of FH multiplied by the mean FG value, 0.455 6) are 0.117, 0.104, 0.028, and 0.030 of Dog-1 to 4, respectively. The values well correspond to F values, 0.143, 0.125, 0.033, and 0.020.
Consequently, we considered that the variability in the plasma concentration of GTS-21 depends on the magnitude of CLH,int, which isˆrst extracted from the liver. Also, we considered that scaling model without blood-plasma partition is suitable for the relationship between in vivo and in vitro pharmacokinetic parameters.
The authors acknowledge that the speciˆcity of chemical inhibitors to canine cytochrome P450 is limited. Canine CYP1A catalyzes phenacetin O-deethylation. 16, 17) The activity is inhibited by furafylline. 16 ) Also, canine CYP1A catalyzes ethoxyresoruˆn O-deethylation, 18) and the activity is inhibited by both a-naphtho‰avone and furafylline.
18) Coumarin 7-hydroxylase activity in dog is lower than that in human, whereas coumarin can act as an inhibitor of canine CYP2A. [16] [17] [18] [19] [20] Diclofenac 4?-hydroxylation can be evaluated as a canine CYP2C substrate. This activity is inhibited by sulfaphenazole. 18) Quinidine and quinine are speciˆc inhibitors of canine CYP2D15. 21, 22) p-Nitrophenol hydroxylation is catalyzed by canine CYP2E1, 23) and can be used as an inhibitor. Troleandomycin is a potent inhibitor of canine CYP3A12. 24, 25) Biphasic Eadie-Hofstee plots suggest at least two CYP enzymes that are involved with GTS-21 O 4-demethylation. To detect high and low a‹nity CYP enzymes, we chose a high concentration of GTS-21 (131 mM). a-Naphtho‰avone, furafylline, quinidine, quinine, and troleandomycin signiˆcantly inhibited GTS-21 O 4-demethylase activity in all dogs. We specied three enzymes, CYP1A, CYP2D15, and CYP3A15 were involved with O 4-demethylation. Among the three enzymes, only CYP1A inhibitors markedly decreased the individual variability in the residual activities. This indicates that CYP1A is a predominant enzyme that controls the individual variability of GTS-21 O 4-demethylation.
Dog expresses CYP3A12 and CYP3A26. 26) The antidog CYP3A12 serum only crosses with CYP3A12. 14) On the other hand, anti-dog CYP1A serum crosses with both CYP1A1 and CYP1A2. As the results of ELISA, the contents of CYP1A for Dogs-1 and 2 were found to be half of those for Dogs-3 and 4 (see Table 4 ). Theˆnd-ing was consistent with the diŠerence in GTS-21 O 4-demethylase activity. This suggests that GTS-21 O 4-demethylase activity is dependent on the content of CYP1A. In other words, the individual diŠerence of the activity is based on quantitative changes, not qualitative ones. The zR.S.D. for CYP3A12 (6.8z) was markedly smaller than that of CYP1A (49.0z). We considered that the content of CYP3A12 did not in‰uence GTS-21 O 4-demethylase activity at all. Taking into consideration of the residual activity in addition of chemical inhibitors, we did not quantify the content of CYP2D15. Because drugs were not administered to the four dogs during in vivo and in vitro studies, enzyme induction or inhibition in the dogs would not be altered.
As results of aboveˆndings, we considered that the contents of canine liver CYP1A caused the individual variability in GTS-21 plasma concentration after oral administration. Although in vivo probe drugs of canine CYP1A are not established so far, we should be cautious the variability in plasma concentration when a high clearance drug that is predominantly metabolized by CYP1A is administered to dogs orally.
In conclusion, comparison in vivo with in vitro pharmacokinetic parameters from a scaling procedure taking into account the protein binding to matrix is useful for characterizing GTS-21 as a hepatic plasma ‰ow-limiting drug. We clariˆed that the canine individual variability in the plasma concentration of GTS-21 after oral administration was caused by aˆrst-pass eŠect that depended on GTS-21 O 4-demethylase activity in liver microsomes. As the results of chemical inhibition study and ELISA, canine CYP1A plays an important role in determining the individual variability of GTS-21 O 4-demethylation.
